Replimune Group (NASDAQ:REPL) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) saw an uptick in trading volume on Tuesday . 10,354,575 shares traded hands during trading, an increase of 128% from the previous session’s volume of 4,542,994 shares.The stock last traded at $6.0720 and had previously closed at $8.63.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Friday, April 10th. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Tuesday, June 30th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $2.00 price objective (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $8.86.

Replimune Group Stock Down 37.6%

The firm’s 50 day simple moving average is $9.34 and its 200-day simple moving average is $7.42. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $452.02 million, a price-to-earnings ratio of -1.59 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last released its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Equities analysts expect that Replimune Group, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. The trade was a 6.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Large investors have recently made changes to their positions in the stock. International Assets Investment Management LLC acquired a new position in Replimune Group during the fourth quarter worth $29,000. CWM LLC grew its position in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the period. Essential Partners LLC grew its position in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Replimune Group during the 2nd quarter worth about $69,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.